Tumor Biology

MTP02 - Critical Aspects in the Diagnosis and Management of MEN1 - Associated Duodenopancreatic Neuroendocrine Tumors

Saturday, June 13, 2026

9:45 AM - 10:25 AM CT

Location: Room W375A

Meet the Professor Speaker(s)

Thor R. Halfdanarson, MD

Rochester, MN, United States
Omair Shariq, MD, PhD

Assistant Professor of Surgery
Mayo Clinic
Rochester, MN, United States

Disclosure(s):

Thor R. Halfdanarson, MD: Biomea Fusion: Advisory Board (); Boehringer Ingelheim: Advisory Board (); Camurus: Clinical Trial Investigator (); Crinetics: Clinical Trial Investigator (); Curium: Advisory Board (); Exelixis: Advisory Board (), Clinical Trial Investigator (); ITM: Clinical Trial Investigator (); Novartis: Clinical Trial Investigator (); Perspective Therapeutics: Clinical Trial Investigator (); RayzeBio: Clinical Trial Investigator (); Rezolute: Clinical Trial Investigator (); Sanofi: Advisory Board (); Thermo Fisher: Clinical Trial Investigator ()

Omair Shariq, MD, PhD: No financial relationships to disclose

Learning Objectives:

Explain the importance of duodenopancreatic neuroendocrine tumors (DP-NETs) as a key manifestation of multiple endocrine neoplasia type 1 (MEN1) and a critical determinant of long-term prognosis.
Guide the diagnostic approach for patients with DP-NETs and MEN1, including when to initiate screening for asymptomatic individuals.
Review the therapeutic management of patients with MEN1-related DP-NETs, including regional therapy, medical therapy, and observation.